肿瘤分子靶向药物治疗进展(2)--在血液系统肿瘤中的应用
首发时间:2005-12-09
摘要:目前用于血液系统肿瘤的分子靶向药物主要是针对细胞表面抗原的单克隆抗体,如利妥昔单抗(Rituximab)、Gemtuzumab Ozogamicin(GO)、阿伦珠单抗(Alemtuzumab)等。几种靶向药物的联合应用或与放、化疗等结合应用,有助于克服耐药性,提高疗效。
关键词: 分子靶向药物 细胞表面抗原 单克隆抗体
For information in English, please click here
Progress of molecular tumor-targeted therapy (2)—on blood malignant diseases
Abstract:Abstract:Recent evidence indicates that treatment with a humanized monoclonal antibody directed at tumor cellular surface antigens improves response and survival in blood malignant diseases, such as Rituximab to CD20, Gemtuzumab Ozogamicin to CD33 , and so on. This conceptual framework, which has guided the search for the combination of different tumor-targeted agents or combined with radiotherapy or chemotherapy to overcome the drug-resistence, is the perspective study .
Keywords: Molecular tumor-targeted therapy Monoclonal antibody
基金:
论文图表:
引用
No.4200259311134089****
同行评议
共计0人参与
勘误表
肿瘤分子靶向药物治疗进展(2)--在血液系统肿瘤中的应用
评论
全部评论0/1000